15.3 Study and Site Closeout Procedures

Study and Site Closeout Procedures

The end of a clinical trial involves much more than simply seeing the last patient for their last visit. Site closeout is a formal, rigorous process that ensures all study data is complete, regulatory obligations are met, and investigational products are properly reconciled. The Clinical Research Coordinator (CRC) orchestrates these final activities, working closely with the sponsor’s Clinical Research Associate (CRA) during the Site Closeout Visit (SCV).

Triggers for Site Closeout

Site closeout activities can be initiated under several circumstances:

1. Routine Completion: The site has successfully completed all protocol-required visits for all enrolled subjects, and the sponsor's database is ready to be locked.
2. Early Termination by Sponsor: The sponsor halts the trial early due to safety concerns (e.g., unacceptable toxicity), overwhelming efficacy, or lack of funding/commercial viability.
3. Early Termination by IRB or FDA: The study is suspended or terminated due to severe compliance issues or unmitigated risks to subjects.
4. Site-Specific Closure: The sponsor closes a specific site due to low enrollment or poor compliance, even while the overall trial continues globally.

Pre-Closeout Activities

Preparation for the SCV should begin weeks before the monitor arrives. The CRC focuses on three primary domains: Data, Investigational Product (IP), and Regulatory Documentation.

1. Data Cleaning and Query Resolution

Before a study can close, the data must be immaculate. The CRC must ensure that all Electronic Case Report Forms (eCRFs) are completed, all data queries generated by the sponsor or data management team are resolved, and the Principal Investigator (PI) has applied their electronic signature to the final data set. All Serious Adverse Events (SAEs) must be fully resolved or stabilized with final reports submitted.

2. Investigational Product (IP) Accountability

Every single pill, vial, or device shipped to the site must be accounted for. The CRC or Investigational Pharmacist must perform final reconciliation:

• Ensure the amount of IP received matches the amount dispensed, returned by subjects, and remaining in inventory.
• Document any missing or lost IP with appropriate explanations.
• Follow sponsor instructions for the remaining IP: this usually involves either destroying the product on-site (with a certificate of destruction) or shipping it back to the sponsor.

3. Regulatory Binder Reconciliation

The Investigator Site File (ISF) must be complete and accurately reflect the timeline of the entire study. The CRC must file final versions of the delegation log, ensure all monitoring visit logs are signed, and verify that the site has copies of all IRB approvals and correspondence.

The Site Closeout Visit (SCV)

The SCV is the final monitoring visit conducted by the CRA. During this visit, the CRA will:

• Conduct a final review of the regulatory binder.
• Perform a final facility inspection (including the pharmacy and lab).
• Verify the return or destruction of the IP.
• Confirm that all biological samples have been shipped to the central laboratory.
• Discuss record retention requirements and publication policies with the PI.

The PI is required to attend a closeout meeting with the CRA to review the final status of the study and acknowledge their ongoing regulatory responsibilities, particularly regarding record retention and FDA inspections.

Post-Closeout Regulatory Requirements

Even after the SCV is complete and the monitor has departed, the site has lingering regulatory obligations.

Final Report to the IRB

The PI is responsible for submitting a final study report to the Institutional Review Board (IRB). This report formally closes the study at the local level and typically includes the total number of subjects enrolled, a summary of all SAEs or unanticipated problems, and confirmation that all study activities have ceased.

Financial and Administrative Closure

The CRC and the site’s financial team must ensure all final invoices are submitted to the sponsor, outstanding subject stipends are paid, and study-specific vendor accounts (e.g., dry ice delivery) are canceled.

Record Retention Requirements

Closing the study does not mean throwing away the files. The site must securely store all study records in a manner that protects subject confidentiality while remaining accessible for future audits.

How long must records be kept?

• FDA Regulations (Drugs): Investigational New Drug (IND) regulations require records to be retained for 2 years following the date a marketing application is approved for the drug. If no application is filed, records must be kept for 2 years after the investigation is discontinued and the FDA is notified.
• Sponsor Requirements: Often, clinical trial agreements (contracts) require sites to retain records much longer than the FDA minimum—sometimes up to 15 or 25 years, depending on international regulations (like the EMA in Europe) or internal company policies.
• Site/Institutional Policies: The site's own institution may have specific retention periods.

Rule of Thumb: The site must follow the most stringent (longest) retention requirement among the FDA, sponsor, and local policies.

The site must never destroy study documents without explicit, written permission from the sponsor. If the PI leaves the institution, they must arrange for the transfer of custodial responsibility for the records and formally notify the sponsor and IRB.

In summary, site closeout is a critical phase that demands meticulous organization. By ensuring accurate data lock, complete IP accountability, and strict adherence to record retention rules, the CRC brings the clinical trial to a compliant and successful conclusion.